Citigroup Inc Biomarin Pharmaceutical Inc Call Options Transaction History

Citigroup Inc

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	SELL	$69.02 - $93.84 $186,354 - $253,368	-2,700 Reduced 9.0%	27,300 $1.92 Million
Q2 2024 Aug 12, 2024	BUY	$74.43 - $92.22 $2.23 Million - $2.77 Million	30,000 New	30,000 $2.47 Million
Q3 2023 Nov 09, 2023	SELL	$85.07 - $94.48 $2.7 Million - $3 Million	-31,700 Reduced 49.38%	32,500 $2.88 Million
Q2 2023 Aug 10, 2023	SELL	$86.68 - $100.3 $6.14 Million - $7.1 Million	-70,800 Reduced 52.44%	64,200 $5.56 Million
Q1 2023 May 11, 2023	BUY	$87.74 - $117.27 $4.54 Million - $6.06 Million	51,700 Added 62.06%	135,000 $13.1 Million
Q4 2022 Feb 09, 2023	BUY	$80.93 - $108.63 $3.91 Million - $5.25 Million	48,300 Added 138.0%	83,300 $8.62 Million
Q3 2022 Nov 10, 2022	BUY	$82.16 - $96.94 $2.88 Million - $3.39 Million	35,000 New	35,000 $2.97 Million
Q1 2022 May 12, 2022	SELL	$74.28 - $92.69 $14.9 Million - $18.6 Million	-200,200 Reduced 85.19%	34,800 $2.68 Million
Q4 2021 Feb 10, 2022	BUY	$71.72 - $91.47 $16.9 Million - $21.5 Million	235,000 New	235,000 $20.8 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.